| 规格: | 98% |
| 分子量: | 399.5 |
| 包装 | 价格(元) |
| 1mg | 电议 |
| 5mg | 电议 |
Background:
BMS 270394 is an agonist of retinoic acid receptor γ (RARγ; EC50= 30 nM in a transactivation assay) and the active enantiomer of BMS 189961 .1It is selective for RARγ over RARβ (EC50= 400 nM) and is inactive at RARα. BMS 270394 synergizes with paclitaxel to inhibit the growth of MCF-7 breast and OVCAR-3 ovarian cancer, as well as SqCC/Y1 head and neck squamous cell carcinoma, cells.2
1.Klaholz, B.P., Mitschler, A., Belema, M., et al.Enantiomer discrimination illustrated by high-resolution crystal structures of the human nuclear receptor hRARγProc. Natl. Acad. Sci. USA97(12)6322-6327(2000) 2.Vivat-Hannah, V., You, D., Rizzo, C., et al.Synergistic cytotoxicity exhibited by combination treatment of selective retinoid ligands with taxol (Paclitaxel)Cancer Res.61(24)8703-8711(2001)
m.cnreagent.com